Detail akcie Kodiak Sciences Rg online

Business Summary: Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kodiak Sciences Inc revenues was not reported. Net loss increased 31% to $173.2M. Higher net loss reflects Interest income decrease of 58% to $3.8M (income), Research and development increase of 3% to $72.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.51 to -$3.28.